Samuel Waksal

(redirected from Samuel D. Waksal)
Also found in: Medical, Wikipedia.

Samuel Waksal

Founder of ImClone, a pharmaceutical company in the United States. While serving as CEO in 2002, he was arrested for insider trading, eventually pleading guilty to securities fraud and similar charges. This scandal was noted for also leading to the arrest of noted television personality Martha Stewart. Waksal was born in 1947.
References in periodicals archive ?
6 million attributable to the withholding tax liability for Samuel D.
The timely accomplishment of this most important milestone is a reflection of the Company's commitment to bring this very important product candidate to patients as quickly as possible," stated Samuel D.
By achieving this milestone we have demonstrated the ability to manufacture clinical supply of IMC-C225 that meets the requirements of international regulatory authorities," stated Samuel D.
This seminal moment for ImClone Systems represents the efforts of not only the Company, but also the oncology community and most importantly the patients, who helped to advance the clinical understanding of IMC-C225," stated Samuel D.
The achievement of the patient randomization milestone in addition to the patient enrollment milestone is a testament to the effective working relationship we maintain with Merck KGaA," stated Samuel D.
The early achievement of this milestone exemplifies the strength of our Phase II data in refractory colorectal cancer and our well managed IMC-C225 clinical trials program," stated Samuel D.
Lily brings valuable leadership and experience in the regulatory aspects of moving an oncology program through clinical testing to product approval and onto the commercial market," stated Samuel D.
As ImClone Systems has pioneered research in this area, the attainment of this milestone in the BEC2 program is a significant event for the Company," stated Samuel D.